EP3332788A1 — Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
Assigned to Opko Renal LLC · Expires 2018-06-13 · 8y expired
What this patent protects
Methods and compositions for treating 25-hydroxyvitamin D insufficiency or deficiency in a patient are described herein. The method includes orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-h…
USPTO Abstract
Methods and compositions for treating 25-hydroxyvitamin D insufficiency or deficiency in a patient are described herein. The method includes orally administering to the patient a sustained release formulation of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3. The 25-hydroxyvitamin D is administered in combination with one or more agents selected from: one or more calcium salts, bisphosphonates, calcimimetics, nicotinic acid, iron, phosphate binders, glycemic control agents, hypertension control agents, and antineoplastic agents.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.